KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$20.7 million.

  • Inovio Pharmaceuticals' Income from Continuing Operations rose 2127.37% to -$20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.9 million, marking a year-over-year increase of 2330.59%. This contributed to the annual value of -$107.8 million for FY2024, which is 2021.03% up from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Income from Continuing Operations stood at -$20.7 million for Q3 2025, which was up 2127.37% from -$22.5 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$19.5 million during Q4 2024, with a 5-year trough of -$108.5 million in Q2 2022.
  • In the last 5 years, Inovio Pharmaceuticals' Income from Continuing Operations had a median value of -$35.5 million in 2023 and averaged -$46.9 million.
  • In the last 5 years, Inovio Pharmaceuticals' Income from Continuing Operations plummeted by 38746.36% in 2021 and then skyrocketed by 6724.85% in 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$106.9 million in 2021, then skyrocketed by 49.07% to -$54.5 million in 2022, then surged by 54.09% to -$25.0 million in 2023, then rose by 21.94% to -$19.5 million in 2024, then fell by 5.85% to -$20.7 million in 2025.
  • Its Income from Continuing Operations was -$20.7 million in Q3 2025, compared to -$22.5 million in Q2 2025 and -$24.2 million in Q1 2025.